ABSTRACT
This chapter discusses the physical and chemical properties of the Re isotopes and the methodologies involved in producing Rhenium (Re)-monoclonal antibodies (MoAb) radioimmunoconjugates. The radiolabeling of MoAb-chelate conjugates with Re, as with technetium (Tc), and unlike protein labeling with other metallic elements, is complicated by the necessity for a Re reducing agent to effect radiolabeling. Reducing agents used for Re radiolabeling may also reduce MoAb disulfide bonds leading to attachment of Re to MoAb at sites other than at the chelate. Antibodies and fragments have been reduced with a variety of agents, primarily for subsequent radiolabeling with Tc. A popular method of radiolabeling MoAbs with Tc is to prereduce the isotope and complex it with a weak chelating agent such as sodium glucoheptonate. The most intensively studied element is Re. The interest in Re for radioimmunotherapy is based on the availability of isotopes of the element which could conceivably be used with MoAb-directed therapy.
